

Annual General Meeting November 2021

REDEFINE QUALITY • DRIVE PRODUCTIVITY

CONFIDENCE IN EVERY SAMPLE

Disclaimer

Material used in this presentation is a summary of available information, and while given in good faith, is professional opinion only. Any investor in Bluechip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering investment in the company.

Certain information may have been derived from third parties and though BCT has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT. Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guarantee in relation to this presentation.

BCT reserves right to update, amend or supplement information in this presentation at any time in its absolute discretion without incurring any obligation to do so.



Bluechiip Fundamentals



**Drives
productivity**



**Redefines
Quality**



**Confidence in
every sample**

- World first, highly differentiated technology: 30 granted patents
- Sophisticated markets: IVF, clinical trials, cell therapies, population biobanking and vaccines require Ultra Low temperature ID and temperature traceability
- Over 300M/yr high value bio-samples preserved/transported at -80°C & -196°C
- >\$600M growing target market with large adjacent markets
- Current ID methods are suboptimal both in productivity and quality
- Capacity built for 5-10 million chips per year, 3m+ in stock
- Major partnership: FujiFilm Industries Irvine Scientific for IVF market
- Direct to market strategy: Bluechiip Enabled Solution Launched Q4 '21
- Cash in bank, \$5m (end Sept), \$1m due in R&D tax refund, zero debt

FY'21 – Key Achievements

- **FujiFilm Industries Irvine Scientific**


- Licence and development agreement for ART/IVF market

- **Bluechiip Enabled solutions launched**

- ISO9001, CFR21-11 software, CE IVD & FDA registration
- Scaled chip supply chain (3m+)
- International ISBER award: Bluechiip Cryobox Tracker
- New market positioning, catalogue, collateral & Website

- **Labcon partnership resolved**

- \$US850k cash received, \$US750k product returned, Credit \$US1.35m



Sample Storage



Readers



Software



Global Product Launch – Bluechiip Enabled Solutions

Bluechiip Enabled Solutions Launched Q4 CY2021

- **Direct-to-market sales and support:** US and ANZ
- **Distribution channels:** EU, APAC and US
- **Initial orders & Installations** in Oct and Nov '21
- **End Market Branding and Communication**
 - New website www.bluechiip.com
 - Product Catalogue [download here](#)



REDEFINE QUALITY • DRIVE PRODUCTIVITY

CONFIDENCE IN EVERY SAMPLE



Sample Storage



Readers



Software

Certifications

- ✓ Certified ISO9001 Quality Management System
- ✓ CE Marked Readers and CE-IVD Marked Consumables
- ✓ FDA Registered Products
- ✓ Bluechiip is a registered Australian Trusted Trader



Bluechiip Overview



Link to corporate video

<https://www.bluechiip.com/investor/company-overview/>

Corporate Overview

Founded in 2003 | Listed on Australian Securities Exchange (ASX) 2011 | IP portfolio: 30 granted patents
Head office in Melbourne, Australia | Direct Sales in North America and Aus/NZ | Global Distribution Partners

Weekly Share Price (cents)



Top Shareholders (as at 15 November 2021)

HSBC Custody Nominees (Australia) Limited	12.75%
---	--------

JP Morgan Nominees Australia Pty Limited	5.46%
--	-------

Chairman & Entities	4.53%
---------------------	-------

Top 20 Shareholders	46.03%
---------------------	--------

Summary

Number of Shareholders	1,678 (15.11.2021)	Market Cap.	AUD34.68m (15.11.2021)
Share Price	5.8c (15.11.2021)	Cash	AUD4.89m (30.09.2021)
Shares on Issue	597,880,502 (15.11.2021)		

Board

Iain Kirkwood Chairman (Nov '07)	Andrew McLellan Managing Director (Jan '15)	Michael O'haneessian Non Exec Dir (Dec '14)	Andrew Cox Non Exec Dir (July '17)
-------------------------------------	--	--	---------------------------------------

Vision

To be the global leader in ID and sensing technology
for extreme environments

Mission

To advance research and medicine by providing
confidence in every sample

Major ID and Sensing Technology Sectors

Primary Focus



Lifesciences Cold Chain incl Logistics, Storage and Monitoring

Item level **ID and temperature tracking** of containers holding high value samples through-out the **cryogenic** cold chain cycle. Including Banking, Transport and Monitoring where **frost** is usually present, and **ID errors have high risk and impact**



Cold Chain Logistics Food

Item level **tracking** of **frozen**, and **temperature sensitive** food products through-out the cold chain cycle.



Industrial and Manufacturing

Item level ID and **high/low temperature tracking** tools and parts, structural health monitoring, items exposed to **ionizing radiation** such as nuclear products, sterilised medical devices, disposables and some food products.



Security and Defence

Anti counterfeiting fashion, art, and high value commercial items. Cloning a bluechiip tag is extremely difficult. tracking of tools and parts that are exposed to **ionizing radiation**, security and defence.

Bluechiip is highly differentiated in Lifescience Cold Chain with core technology benefits and large market opportunity

Life-science Cold Chain Market Trends



Increasing sample numbers and retrieval rates

PRODUCTIVITY

Minimise total cost of sample ownership and ROI



Increased demand for advanced therapies and sensitive samples

SAMPLE VALUE

ID tech needs to keep up with higher value samples



Criticality of sample history maps and reports

SAMPLE QUALITY

Maximise specimen integrity via adequate cold chain handling and reporting



Increasing demand for cryo (-196°C and -80°C) storage

CRYO TECH

Utilisation of cryo-safe technology and processes

Biosample Management Technology is Not Keeping up With the Increasing Value of Biosamples

Tissue

Blood

IVF Sperm/Eggs

Vaccines


Stem Cell



Primary Market Opportunity

Global Bio-Preservation Market \$3.1B in 2020
– Projected \$4.9B in 2025 (CAGR 9.2%)^

Samples in Storage*



Sources: ^Markets and Markets 2020 *Visual Fuse and MarketsandMarkets 2014

Primary Bluechiip Applications

Life Science Market Opportunities









Target Market	Market Size by Samples	Bluechiip Addressable Market
Bio-preservation	300m+ samples/year >2B in storage	US\$600m+
Assisted Reproductive Technology (IVF)	2.5m IVF Cycles/year 5-8 consumables per cycle >33m samples in storage	US\$50m+
Clinical trials and research	>35m samples/year	US\$70m+
Cell therapies, Pharmaceuticals	3m samples/year 15m+ in storage	US\$30-50m+


Total Bio-Preservation: 2B Samples in Storage
300M new samples per year

Sources: Visual Fuse and Markets and Markets 2014

Bluechiip MEMS Core Technology Advantages

Bluechiip's sensor tag consists of a silicon chip (1mm²) with 52 mechanical beams that provide a unique ID when read. The chip is connected to an antenna available in multiple form factors, providing communication of both ID and temperature to a centralized database. Bluechiip's Tag provides key advantages over other forms of ID in cryogenic conditions.

	 RFID	 Barcodes	 Bluechiip
 Non-visual ID Reads through frost	~*	✗	✓
 Cryosafe Operates down to -196C	✗	✗	✓
 Guaranteed unique ID ID cannot be overwritten or duplicated	✗	✗	✓
 On-board sensor Senses temperature on each scan	✗	✗	✓
 Sterilization proof Gamma, E-beam, Autoclave	✗ [^]	✓	✓




*Majority of RFID unreliable below -40C. ^Some newer RFID's have resistance

Bluechiip offers the only Advanced Sample Management solution that provides **sample temperature with ID** in cryogenic environments

We understand that every sample is critical and managing each one with optimal quality, in the most efficient way is the objective

Bluechiip Enabled Storage



Bluechiip Readers



Bluechiip Stream Software



Bluechiip's goal is to deliver confidence in every sample



Confidence in Every Sample

Bluechiip's unique and patented technology is designed to operate across a wide temperature range from -196°C to over +100°C, creating the perfect system for managing sensitive samples. Bluechiip Enabled Sample Storage, Readers and Software combine to provide an unparalleled ability to track and store sample level data, including temperature across the cold chain process.

Redefining Quality

- ✓ Capturing ID and temperature at the sample level for cold chain integrity
- ✓ Reducing the risk of temperature excursions in cryogenic conditions
- ✓ Providing key workflow insights to drive continuous improvement
- ✓ Eliminating errors through optimized inventory management
- ✓ Enabling compliance to industry standards and internal procedures



Driving Productivity

- ✓ Reducing manual processes and eliminating double witnessing
- ✓ Identifying multiple samples instantly through frost
- ✓ Simplifying inventory handling for faster processing
- ✓ Driving efficiency at every step of the workflow



Bluechiip Path to Market

Bluechiip Direct Solutions

- Direct to market: North America, ANZ and global distribution network
- Consumables, Readers, Software Sales model

Primary Target Markets

- Bio-preservation
- Clinical trials and research
- Cell therapies & Pharmaceuticals



Partnerships: Bluechiip Enabled Solutions

- Developer kits sold to global corporations for due diligence
- Conversion to licence agreements and Bluechiip Enabled solutions
- Ongoing licence fees
- Development and service revenues
- Sale of Bluechiip Enabled Consumables, readers & software

Major Licence agreements

- FujiFilm Industries Irvine Scientific
 - Licence and Development agreement
 - 18-24 month development project
- Labcon distribution agreement



Foundations Set



- World first, highly differentiated technology: 30 granted patents
- Sophisticated markets: IVF, clinical trials, cell therapies, population biobanking and vaccines require Ultra Low temperature ID and temperature traceability
- >300M/yr high value bio-samples preserved & transported in -80°C/-196°C environments
- >\$600M growing target market with large adjacent markets
- Current ID methods are suboptimal both in productivity and quality
- Capacity built for 5-10 million chips per year, 3m+ in stock
- Major partnership: FujiFilm Industries Irvine Scientific in IVF
- Direct to market strategy: Bluechip Enabled Solution Launched
- Cash in bank, \$5m end Sept, \$1m R&D tax refund due, zero debt



Contact

Andrew McLellan

Managing Director & CEO

Telephone +61 (0)3 9763 9763

Mobile +61 (0)457 823 470

Email andrew.mclellan@bluechiip.com

bluechiip.com